02/11/2022 - 13:26

University deal to boost cancer research for Chimeric

02/11/2022 - 13:26

Bookmark

Save articles for future reference.

ASX-listed biotech company Chimeric Therapeutics has signed a sponsored research deal with Case Western Reserve University in the United States to develop the company’s NK cell therapy portfolio to assist in its fight against cancer. One of Chimeric’s key missions is to cure cancer, not simply slow its progress, by developing cutting-edge cell therapy treatments aimed at killing the molecules that drive cancer cells and promote metastases.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options